pro 2021 software (treeage software)
90
Structured Review
treeage software
pro 2021 software
Pro 2021 Software, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2021+software/pro+2022+software/pm40293642-49-7-7
Average 90 stars, based on 1 article reviews
Pro 2021 Software, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pro+2021+software/pro+2022+software/pm40293642-49-7-7
Average 90 stars, based on 1 article reviews
pro 2021 software - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Software:Article Title: Cost-utility analysis of different venous access devices in breast cancer patients: a decision-based analysis model Article Snippet: .. Article Title: Improving neglected tropical disease services and integration into primary healthcare in Southern Nations, Nationalities and People's Region, Ethiopia: Results from a mixed methods evaluation of feasibility, acceptability and cost effectiveness. Article Snippet: .. The Article Title: Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial Article Snippet: .. To estimate the cost-effectiveness of implementing AHCL therapy compared to SoC in pregnant women with T1D, a decision tree model was constructed using Article Title: Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis. Article Snippet: Background Several economic studies have assessed the cost-effectiveness of programmed cell death protein-1 (PD-1) inhibitors compared to second-line chemotherapy in treating esophageal squamous cell carcinoma (ESCC).. However, there is a lack of economic comparisons among the different PD-1 inhibitors.. Aim This study aimed to assess the cost-effectiveness of PD-1 inhibitors (nivolumab, pembrolizumab, camrelizumab, and tislelizumab) in second-line treatment for advanced or metastatic ESCC within the Chinese healthcare system. Article Title: Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States. Article Snippet: Purpose: Trastuzumab deruxtecan has been shown to be effective for advanced breast cancer with low levels of human epidermal growth factor receptor 2.. To optimize the allocation of limited health care resources, this study evaluated the cost-effectiveness of trastuzumab deruxtecan from the US payer perspective.. Methods: A partitioned survival model was developed to project the disease course of advanced breast cancer. Article Title: Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China. Article Snippet: Background The CD20 × CD3 bispecific antibody glofitamab combined with gemcitabine and oxaliplatin (Glofit-GemOx) has demonstrated clinical efficacy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).. Aim The aim of this study was to evaluate the cost-effectiveness of Glofit-GemOx versus R-GemOx for relapsed or refractory DLBCL patients following one or more previous lines of therapy from the perspective of healthcare in China.. Method A three-state partitioned survival model was constructed based on the STARGLO study to assess the cost-effectiveness of Glofit-GemOx versus rituximab-GemOx (R-GemOx). Construct:Article Title: Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial Article Snippet: .. To estimate the cost-effectiveness of implementing AHCL therapy compared to SoC in pregnant women with T1D, a decision tree model was constructed using Article Title: Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis. Article Snippet: Background Several economic studies have assessed the cost-effectiveness of programmed cell death protein-1 (PD-1) inhibitors compared to second-line chemotherapy in treating esophageal squamous cell carcinoma (ESCC).. However, there is a lack of economic comparisons among the different PD-1 inhibitors.. Aim This study aimed to assess the cost-effectiveness of PD-1 inhibitors (nivolumab, pembrolizumab, camrelizumab, and tislelizumab) in second-line treatment for advanced or metastatic ESCC within the Chinese healthcare system. Article Title: Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China. Article Snippet: Background The CD20 × CD3 bispecific antibody glofitamab combined with gemcitabine and oxaliplatin (Glofit-GemOx) has demonstrated clinical efficacy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).. Aim The aim of this study was to evaluate the cost-effectiveness of Glofit-GemOx versus R-GemOx for relapsed or refractory DLBCL patients following one or more previous lines of therapy from the perspective of healthcare in China.. Method A three-state partitioned survival model was constructed based on the STARGLO study to assess the cost-effectiveness of Glofit-GemOx versus rituximab-GemOx (R-GemOx). Biomarker Discovery:Article Title: Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis. Article Snippet: Background Several economic studies have assessed the cost-effectiveness of programmed cell death protein-1 (PD-1) inhibitors compared to second-line chemotherapy in treating esophageal squamous cell carcinoma (ESCC).. However, there is a lack of economic comparisons among the different PD-1 inhibitors.. Aim This study aimed to assess the cost-effectiveness of PD-1 inhibitors (nivolumab, pembrolizumab, camrelizumab, and tislelizumab) in second-line treatment for advanced or metastatic ESCC within the Chinese healthcare system. other:Article Title: The UK resuscitative endovascular balloon occlusion of the aorta in trauma patients with life-threatening torso haemorrhage: the (UK-REBOA) multicentre RCT Article Snippet: A decision analysis model was created using |